Eli Lilly
Also known as: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | DISTA | Eil Lilly and Company | ELI LILLY AND CO | Eli Lilly and Company | ELI LILLY CO | Experior | Experior S.L. | LILLY | LILLY RES LABS | Lily Research Laboratories | LOXO ONCOL ELI LILLY | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | National Institute of Mental Health, Eli Lilly & Co. | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company | Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Highest phase reached
Phase 4
First clinical trial
Feb 1, 1989First marketed drug
Jun 1, 1923First NDA
Jun 1, 1923Last known activity
Aug 1, 2026
Timeline
1870s
- Jan 1, 1876
Eli Lilly— Founded
1960s
- Apr 7, 1967
phenoxymethylpenicillin— Marketing Organization
1970s
- Jan 1, 1971
Elizabeth Arden— Acquired
- Apr 9, 1976
dicoumarol— NDA Organization
- Jan 1, 1977
Cardiac Pacemakers, Inc— Acquired
- Jan 1, 1977
IVAC— Acquired
1980s
- Jan 1, 1980
Physio-Control Corporation— Acquired
- Jan 1, 1985
Hybritech— Acquired
- Jan 1, 1989
Devices for Vascular Intervention, Inc— Acquired
1990s
- Jan 1, 1990
IASO Pharma Inc.— Acquired
- Jan 1, 1992
Origin Medsystems— Acquired
2000s
- Feb 12, 2004
Applied Molecular Evolution— Acquired
- Jan 1, 2007
ICOS— Acquired
- Jan 1, 2008
SGX Pharmaceuticals— Acquired
- Nov 24, 2008
Imclone— Acquired
2010s
- Jan 1, 2010
Alnara Pharmaceuticals— Acquired - Nov 8, 2010
Avid Radiopharmaceuticals— Acquired - Apr 6, 2012
florbetapir— NDA Secondary Org
- Jun 1, 2013
ARMO BioSciences— Acquired
- Jan 18, 2017
CoLucid Pharmaceuticals— Acquired
- May 14, 2018
AurKa Pharma Inc.— Acquired
- Jan 7, 2019
Loxo Oncology— Acquired
2020s
- Jan 10, 2020
Dermira, Inc.— Acquired
- Dec 15, 2020
Prevail Therapeutics— Acquired
- Jul 14, 2021
Protomer Technologies— Acquired
- Jun 20, 2023
DICE Therapeutics, Inc.— Acquired
- Aug 14, 2023
Sigilon Therapeutics, Inc.— Acquired
- Aug 14, 2023
Versanis Bio, Inc.— Acquired
- Oct 3, 2023
POINT Biopharma— Acquired
- Oct 18, 2023
Akouos, Inc.— Acquired
- May 16, 2025
Rznomics, Inc.— Acquired
- May 27, 2025
SiteOne Therapeutics— Acquired
- Jun 17, 2025
Verve Therapeutics, Inc.— Acquired
- Oct 24, 2025
Adverum Biotechnologies, Inc.— Acquired
- Nov 10, 2025
MeiraGTx— Acquired
Drugs by trial phase (681 distinct, 2795 trials)
Phase 4 (85 own, 16 via acquisition)
Phase 3 (79 own, 60 via acquisition)
Phase 2 (170 own, 47 via acquisition)
Phase 1 (175 own, 42 via acquisition)
Other trials (6 own, 1 via acquisition)
Indications
Approved for
- Acne Vulgaris
- Acute Coronary Syndrome
- Acute Pain
- Anxiety Disorders
- Arrhythmias, Cardiac
- Arthritis, Rheumatoid
- Atrial Fibrillation
- Attention Deficit Disorder with Hyperactivity
- Bacterial Infections
- Bipolar Disorder
- Blood Coagulation
- Bone Diseases, Infectious
- Breast Neoplasms
- Bronchitis, Chronic
- Bulimia Nervosa
- Carcinoma, Non-Small-Cell Lung
- Cardiac Output, Low
- Cardiovascular Diseases
- Chronic Pain
- Conjunctivitis, Allergic
- Cystic Fibrosis
- Dermatitis Herpetiformis
- Diabetes, Gestational
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diphtheria
- Endocarditis
- Endocarditis, Bacterial
- Erectile Dysfunction
- Erythrasma
- Eye Infections, Bacterial
- Female Urogenital Diseases
- Fibromyalgia
- Gastroparesis
- Heart Diseases
- Heart Failure
- Hepatitis C
- Hepatitis C, Chronic
- Histiocytosis, Langerhans-Cell
- Hodgkin Disease
- Hypertension
- Hyperthyroidism
- Hypoglycemia
- Infections
- Inflammation
- Leukemia, Lymphoid
- Listeriosis
- Lymphoma, Non-Hodgkin
- Major Depressive Disorder
- Malaria, Falciparum
- Mesothelioma
- Migraine Disorders
- Muscle Relaxation
- Mycosis Fungoides
- Nausea
- Obsessive-Compulsive Disorder
- Opioid-Related Disorders
- Osteoporosis
- Osteoporosis, Postmenopausal
- Otitis Externa
- Otitis Media
- Ovarian Neoplasms
- Pain
- Pancreatic Neoplasms
- Panic Disorder
- Parkinson Disease
- Peritonitis
- Pharyngitis
- Pituitary ACTH Hypersecretion
- Pneumonia
- Pneumonia, Mycoplasma
- Preanesthetic Medication
- Prostatic Hyperplasia
- Psoriasis
- Psychomotor Agitation
- Respiratory Tract Infections
- Sarcoma
- Sarcoma, Kaposi
- Schizophrenia
- Sepsis
- Skin Diseases, Infectious
- Sleep Initiation and Maintenance Disorders
- Staphylococcal Infections
- Staphylococcal Skin Infections
- Stomach Diseases
- Tachycardia
- Testicular Neoplasms
- Tonsillitis
- Tuberculosis, Pulmonary
- Urinary Tract Infections
Studied for
- Acute Coronary Syndrome
- Acute Disease
- Acute Lung Injury
- Acute Pain
- Adenocarcinoma
- Aggression
- Albuminuria
- Alcoholism
- Alopecia
- Alopecia Areata
- Alzheimer Disease
- Anemia
- Anemia, Refractory
- Anemia, Refractory, with Excess of Blasts
- Anemia, Sickle Cell
- Anorexia
- Anorexia Nervosa
- Anxiety Disorders
- Arteriosclerosis
- Arteritis
- Arthritis
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asthma
- Atrophy
- Attention Deficit and Disruptive Behavior Disorders
- Attention Deficit Disorder with Hyperactivity
- Autism Spectrum Disorder
- Autistic Disorder
- Autoimmune Diseases
- Autoimmune Diseases of the Nervous System
- Back Pain
- Bile Duct Neoplasms
- Biliary Tract Neoplasms
- Binge-Eating Disorder
- Bipolar Disorder
- Body Weight
- Bone Marrow Diseases
- Bone Neoplasms
- Borderline Personality Disorder
- Brain Diseases
- Brain Injuries
- Brain Injuries, Traumatic
- Brain Ischemia
- Brain Neoplasms
- Brain Stem Neoplasms
- Breast Neoplasms
- Breast Neoplasms, Male
- Bulimia
- Cancer Pain
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Hepatocellular
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Carcinosarcoma
- Cardiovascular Diseases
- Carotid Stenosis
- Central Nervous System Diseases
- Cervical Intraepithelial Neoplasia
- Cholangiocarcinoma
- Cholangitis
- Chondrosarcoma
- Chordoma
- Chorea
- Choriocarcinoma
- Chronic Pain
- Cluster Headache
- Cocaine-Related Disorders
- Cognition Disorders
- Cognitive Dysfunction
- Colitis
- Colitis, Ulcerative
- Colles' Fracture
- Colonic Neoplasms
- Colorectal Neoplasms
- Common Cold
- Compulsive Personality Disorder
- Connective Tissue Diseases
- Constriction, Pathologic
- Coronary Artery Disease
- Coronary Disease
- Coronary Restenosis
- Coronary Stenosis
- Coronavirus Infections
- Crohn Disease
- Dementia
- Depression
- Depressive Disorder
- Depressive Disorder, Treatment-Resistant
- Dermatitis
- Dermatitis, Atopic
- Dermatitis, Exfoliative
Marketed drugs (117)
Subsidiaries (31 direct, 31 total across the full acquisition tree)
- Adverum Biotechnologies, Inc.
- Akouos, Inc.
- Alnara Pharmaceuticals
- Applied Molecular Evolution
- ARMO BioSciences
- AurKa Pharma Inc.
- Avid Radiopharmaceuticals
- Cardiac Pacemakers, Inc
- CoLucid Pharmaceuticals
- Dermira, Inc.
- Devices for Vascular Intervention, Inc
- DICE Therapeutics, Inc.
- Elizabeth Arden
- Hybritech
- IASO Pharma Inc.
- ICOS
- Imclone
- IVAC
- Loxo Oncology
- MeiraGTx
- Origin Medsystems
- Physio-Control Corporation
- POINT Biopharma
- Prevail Therapeutics
- Protomer Technologies
- Rznomics, Inc.
- SGX Pharmaceuticals
- Sigilon Therapeutics, Inc.
- SiteOne Therapeutics
- Versanis Bio, Inc.
- Verve Therapeutics, Inc.
Recent trials (50)
- NCT03763604Lead sponsorN/A—
- NCT03906331CollaboratorN/A—
- NCT05225259Lead sponsorN/A—
- NCT05172700Study directorN/A—
- NCT04603651Lead sponsorN/A—
- NCT04603651Study directorN/A—
- NCT03994627Lead sponsorN/A—
- NCT06911944CollaboratorPhase 4Aug 1, 2026
- NCT07218341OfficialPhase 4Mar 31, 2026
- NCT07218341Lead sponsorPhase 4Mar 31, 2026
- NCT07222332OfficialPhase 3Mar 31, 2026
- NCT07222332Lead sponsorPhase 3Mar 31, 2026
- NCT07191873CollaboratorPhase 4Feb 28, 2026
- NCT07226843Lead sponsorPhase 1Feb 28, 2026
- NCT07226843OfficialPhase 1Feb 28, 2026
Details
- Founded
- Indianapolis, IN, US Jan 1, 1876
- First NDA
- Jun 1, 1923
- Last known activity
- Aug 1, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval
Notes
--- Notes from Experior: CRO ---